2025-06-10-Bernstein-直觉外科公司（ISRG）_直觉外科_翻新仪器与外太空的智能生命_两者皆无需担忧_16页_2mb

Investment Research Summary: Intuitive Surgical Inc (ISRG)

• Rating and Price Target: BernSTEIN rates ISRG "Outperform" with an unchanged price target of $675. The stock experienced a brief dip to $500 (-10.3%) due to concerns about remanufactured instruments but recovered.

• Core Concern Addressed: Third-party companies can remanufacture used da Vinci EndoWrist instruments, offering discounts up to 30%. BernSTEIN counters that this is not a significant threat due to safety risks, liability issues, scalability challenges, and other factors, emphasizing ISRG's long-term recurring revenue model.

• Key Counter-Arguments:

  • Safety and Liability: Hospitals cannot guarantee patient safety with third-party modifications, and liability questions arise.
  • Industrial Scale: ISRG has invested in robust supply chains essential for hospital operations, which is hard for small players to match.
  • Risk and Reward: The price discount may not justify the additional risk and complexity for hospitals or surgeons.
  • Pricing Structure: ISRG's instruments include bundled services and support, making direct comparisons with third-party offerings inaccurate.
  • Generational Gap: Remanufacturing is easier for older Gen-4 instruments, but newer Gen-5 systems with force feedback are less amenable, benefiting ISRG.
  • Digital Shift: ISRG's digital capabilities (e.g., AI-driven Case Insights) will drive future revenue and mitigate potential declines.
  • Strong Leadership: Management is positioned to defend against threats effectively.

• Financial Highlights: ISRG maintains strong growth, with I&A revenue comprising 61% of total revenue in 2024. Adjusted EPS is projected to grow significantly over the next few years, offering more upside than any other stock in coverage. Financial metrics show high operating margins and steady revenue expansion.

• Product Pipeline: ISRG is set for transformative launches, including dV5, AI enhancements, Ion catheter, SP system, and refurbished Xi systems. These innovations are expected to drive inflection points and margin improvements.

• Bottom Line: Despite market concerns, BernSTEIN maintains confidence in ISRG's long-term prospects, citing its superior product cycle and financials. They recommend purchasing at current levels to capture upside.